UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics files S‑3, becomes Nasdaq‑listed, and boosts CEO‑CFO RSUs while advancing kidney‑care therapies, aiming for breakthrough growth.

Unicycive Therapeutics: Pioneering hyperphosphatemia treatments for CKD & AKI patients, driving innovative kidney care while navigating biotech growth challenges.

Unicycive Therapeutics’ stock climbs after a standout Needham conference, boosting investor confidence and highlighting its pioneering kidney‑health therapies.

Unicycive Therapeutics faces a critical juncture after a director’s resignation and volatile stock, prompting investors to scrutinize its financial health and kidney‑disease therapy pipeline for sustainable growth.

Unicycive Therapeutics sees analyst downgrade: Guggenheim cuts target price after reassessment, prompting investors to re‑evaluate its kidney‑care drug pipeline.

Unicycive Therapeutics reports Q4 2025 results: a $0.82 per-share loss, narrowing from $2.60 last year, and near‑break‑even full‑year EPS of $1.67.

Unicycive Therapeutics: No new developments or financial updates, only current fundamentals remain unchanged.

Unicycive Therapeutics secures FDA approval to review its oxylanthanum carbonate for hyperphosphatemia—boosting hopes for kidney‑disease treatment and investor growth.

Unicycive Therapeutics wins FDA acceptance for its kidney‑disease drug oxylanthanum carbonate, but an investor probe looms—will the approval spark a share rally or trigger caution?

Unicycive Therapeutics faces volatility as it pursues hyperphosphatemia treatments for kidney disease patients, seeking breakthroughs amid financial uncertainty.